MAP1LC3A and type 1 diabetes mellitus: However, in 129 sve 5LO−/− T1D mice, we have only observed a decrease in the expression of Atg12 (5LO−/− T1D vs 5LO−/− T1D + Cap p = 0.0143) and LC3 (5LO−/− + Cap vs 5LO−/− T1D p = 0.0130; 5LO−/− T1D vs 5LO−/− T1D + Cap p = 0.0187), and the treatment with Cap restored the expression of these genes (Fig. 8B, D, F, H, J, L), indicating that the presence of LTs may be related to the functioning of this pathway, and that Cap treatment could improve the activation of this pathway.